Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Physical Therapists Advocate On Capitol Hill For Access To Rehabilitative Services
Two hundred physical therapists, physical therapist assistants, and students of physical therapy marched on Capitol Hill Tuesday to educate lawmakers about the critical need for patients to have improved access to physical therapy services. The group-members of the American Physical Therapy Association (APTA)-conducted approximately 350 visits with Representatives and Senators.
buy viagra
Addex Partner Starts First-Ever Clinical Trial Of An MGluR Positive Allosteric Modulator
Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that its partner Ortho-McNeil- Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, depression and other CNS disorders, is the first PAM of any mGluR subtype to enter clinical trials. Targeting mGluR2 with a PAM is a novel approach that may offer advantages over classical drug approaches. In reaching this milestone, Addex received a EUR 1 million payment from OMP and remains eligible for additional development milestones and royalties.
plan for health
News of the day
Senate Democrats Meet With White House Adviser To Craft Response To Republican Criticism On Health Reform
Senate Democrats on Wednesday worked with senior White House adviser David Axelrod to craft a health care message focused on affordability and choice, the AP/Contra Costa Times reports (Werner, AP/Contra Costa Times, 5/13). The meeting followed the release of a memo last week by Republican strategist Frank Luntz outlining how to criticize Democratic plans for health reform (Budoff Brown/McGrane, Politico, 5/13). Senate Majority Whip Richard Durbin (D-Ill.) said Luntz"s memo was "an interesting catalyst for us" (AP/Contra Costa Times, 5/13).Axelrod presented Democrats with polling data about what U.S. residents are seeking from a health care overhaul and discussed better word choices, such as "shared responsibility" rather than "mandates" for coverage requirements. According to CongressDaily, the meeting centered Democrats on a coordinated message that the U.S. health care system must be affordable and accessible and should be patient-focused (Edney/Condon, CongressDaily, 5/13). Sen. Evan Bayh (D-Ind.) said that many Democrats felt "unease that we did not have a strategy" to answer the attacks coming from Republicans (Pear, New York Times, 5/14). Senate Finance Committee Chair Max Baucus (D-Mont.) said, "Everybody in the room had been a little nervous that, "Gee, Democrats don"t have their act together"" (CongressDaily, 5/13). However, Bayh said that "Axelrod came to reassure us that they do have a strategy" (New York Times, 5/14). Durbin said, "This is an effort to coordinate our message so we present a health care reform effort the American people trust" (Armstrong, CQ Today, 5/13). According to Durbin, Axelrod emphasized that Democrats should continue with the campaign theme that the goal of an overhaul is to "fix what"s broken in the system and preserve what"s good" (Young, The Hill, 5/13).Sen. Charles Schumer (D-N.Y.) said, "We believe the public shares our views. But we don"t want to be overwhelmed by either res, messaging or boots on the ground." He added, "We won"t make the mistake of 1993-94." According to the New York Times, a plan developed by the administration of former President Clinton "collapsed" in the face of Republican criticism (New York Times, 5/14).
Health Insurance

Novel Role Of Gene May Provide Key To Treating Liver And Neurodegenerative Diseases

Scientists at Singapore"s Bioprocessing Technology Institute (BTI) have made a novel discovery about how the gene, "Fas-apoptosis inhibitory molecule" (FAIM), protects both immune and liver cells from apoptosis, or programmed cell death. Their research is published in the current journal Cell Death and Differentiation. The scientists, Jianxin Huo, Ph.D., and Shengli Xu, Ph.D., also discovered that this process may possibly be manipulated for clinical application and proposed the first-to-be-published in-animal model to study the role of FAIM in detail. FAIM triggers a mechanism that ultimately impedes an important pathway to apoptosis, which is mediated by a key protein called Fas. Using their mouse model, the scientists elucidated part of the sequence of molecular events that regulates Fas-mediated apoptosis. They found that FAIM functioned as a key switch in the Fas cell death circuit, which could be turned up or down to prolong or decrease cell survival. Therefore, in principle, this gene could make a good target for drug intervention in either liver cirrhosis in which the target is to prolong cell survival, or in cancer in which the goal is to induce tumour cell death. BTI Scientific Director Lam Kong Peng, Ph.D., who heads the immunology group that conducted the research, said, "We had earlier identified FAIM to be valuable in increasing the yield of biologics, and that had been one of the main focuses of BTI"s research until now. We were extremely pleased to be able to establish that FAIM"s function is preserved across both liver and immune cells, as this underscores its critical role in regulating cell death in disease." The immunology team at BTI, one of the research institutes sponsored by Singapore"s A*STAR (Agency for Science, Technology and Research), aims to further characterize the role of FAIM in liver cancer and other debilitating diseases. According to Drs. Huo and Xu, there is also significant existing evidence that FAIM prevents neuron death and promotes neural outgrowth. They hypothesize that FAIM might play a role in neuron protection, making it a potential therapeutic target for neurodegenerative diseases such as Alzheimer"s and Parkinson"s. Eventually, the Singapore scientists hope to conduct drug screens on FAIM to determine how it can be used to prolong or delay cell survival, and provide solutions to a wide variety of human diseases. Drs. Huo and Xu"s interest in FAIM was sparked by the work of their colleagues in BTI"s animal cell technology group, which since 2007 has been using FAIM to enhance the longevity of biologics-producing cells to increase their yield in bioreactors, which are vessels in which organisms are cultured, and biochemically active substances derived from them. Biologics are medicinal products such as vaccines, allergenics, tissues and recombinant proteins that can be extracted from natural s (human, animal, or microorganism) and produced by biotechnology methods. Curious about FAIM"s role in immune cells, particularly its increased expression in activated B cells, key effectors of the human immune system responsible for fighting viruses and other pathogens that invade the body, the two scientists began developing the first in vivo knockout mouse model to closely examine FAIM"s role in preventing programmed cell death. BTI Executive Director Miranda Yap, Ph.D., said, "The Immunology Group"s venturing beyond the traditional boundaries of applied science has paid off with their discovery of a second role for FAIM in the seemingly unrelated field of immunology. Their work is indeed a fine example of how our scientists are constantly pushing the envelope to keep at the forefront of biomedical research." The Cell Death and Differentiation paper, "Genetic deletion of faim reveals its role in modulating c-FLIP expression during CD95-mediated apoptosis of lymphocytes and hepatocytes," is authored by: J. Huo, S. Xu, K. Guo, Q. Zeng and K-P Lam. Cathy Yarbrough Agency for Science, Technology and Research (A*STAR), Singapore


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009